Celgene Sets Sights On Becoming Inflammation and Immunology Power Player
Celgene will buy Receptos for $7.2 billion, gaining the late-stage drug ozanimod in development for multiple sclerosis and ulcerative colitis. With the addition of ozanimod, the company will have three late-stage drugs in its inflammation and immunology portfolio.
You may also be interested in...
Celgene, in need of good news, posted positive data on a potential blockbuster for multiple sclerosis at the joint ECTRIMS-ACTRIMS meeting. Ozanimod could have important safety and tolerability advantages over Gilenya, but investors already were expecting good news.
Celgene will stop late-stage testing of its investigative therapy mongersen for Crohn’s disease after a data monitoring committee said it would be futile to continue.
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.